SCHEMBL23055145

SCHEMBL23055145

Cc1cccc(C(C)c2ccc(F)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 2/20 0.41
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GBA1 P04062 1/20 0.39
TP53 P04637 1/20 0.39
CCR1 P32246 1/20 0.38
CCR8 P51685 1/20 0.38
TGFBR1 P36897 1/20 0.37
HSD11B1 P28845 1/20 0.37
ALOX5AP P20292 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
DAO P14920 1/20 0.35
IDO1 P14902 2/20 0.34
TDO2 P48775 2/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4333513 0.83 HTT (0.50) TRPV3HTTRECQLNPC1RAB9A
SCHEMBL21910148 0.83 KCNE1 (0.39) TRPV3HTTRECQLNPC1RAB9A
SCHEMBL21831335 0.81 CNR2 (0.46) HTTRECQLNPC1RAB9AGBA1
SCHEMBL30910868 0.81 CNR2 (0.46) HTTRECQLNPC1RAB9AGBA1
SCHEMBL25482249 0.77 HTT (0.41) TRPV3HTTRECQLCCR1CCR8
SCHEMBL5655555 0.77 L3MBTL1 (0.51) HTTRECQLNPC1RAB9AGBA1
SCHEMBL6631092 0.77 HTT (0.39) HTTRECQLNPC1RAB9AGBA1
SCHEMBL28857385 0.76 RAB9A (0.43) HTTRECQLNPC1RAB9AGBA1
SCHEMBL23287487 0.75 HTT (0.39) HTTRECQLCCR1CCR8NOS3
SCHEMBL56844 0.73 SLC6A3 (0.46) KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG TRPV3 1550/4885HTT 4810/4885RECQL 914/4885
US-20210061802-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG TRPV3 1550/4885HTT 4810/4885RECQL 914/4885
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG TRPV3 1464/4885HTT 4775/4885RECQL 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.